CDH1 and lung cancer: Besides MM, miR-25 has been documented to promote triple-negative breast cancer and glioma progression through the activation of AKT/MAPK-ERK pathway and the suppression of PTEN, respectively [50, 51] while in lung cancer, miR-25 facilitates lymph node metastasis by targeting CDH1, and correlates with significantly worse patients’ outcome [52].